Dermal Filler Comparison Guide by Type, Area & Longevity

HA fillers dominate the market because they are reversible, predictable, and FDA-cleared for multiple indications. The key variable is crosslink density—how tightly the HA polymer chains are bonded—which determines how long the filler persists and how much lift it provides.

• Light-crosslink HA (Restylane Silk, Juvéderm Ultra XC) lasts 6–9 months; ideal for lips, fine lines, and delicate areas where a natural feel matters more than projection
• Medium-crosslink HA (Restylane, Juvéderm Ultra Plus XC, Belotero) lasts 9–12 months; the workhorse for nasolabial folds, marionette lines, and moderate volume loss
• Heavy-crosslink HA (Restylane Lyft, Juvéderm Voluma XC, Juvederm Volux XC) lasts 12–18 months; designed for deep folds, cheek augmentation, and jawline definition where structural support is required

Crosslink density also affects spreadability: lighter formulations diffuse more readily (useful for blending), while denser products stay localized (better for sculpting). Allergan Aesthetics (AbbVie) and Galderma dominate HA market share; Evolus (Nucelis) competes on price and rebate structure. HA is metabolized by hyaluronidase, so patients can request reversal if over-correction occurs—a clinical and medicolegal advantage.

Biostimulators work differently from HA: they do not fill directly but trigger collagen deposition over weeks to months, creating gradual, sustained volume that can last 2+ years. They are ideal for patients seeking longevity and a natural progression.

• Polylactic acid (PLLA): Sculptra (Galderma) is the category leader. Injected in dilute suspension, it stimulates fibroblasts to produce new collagen. Results appear over 4–6 weeks and peak at 3 months; duration is 24+ months. Cost per vial is higher upfront, but longevity and reduced touch-up frequency lower patient lifetime cost. Requires post-injection massage and multiple treatment sessions (typically 3, spaced 4–6 weeks apart)
• Calcium hydroxylapatite (CaHA): Radiesse (Galderma) provides immediate volumization (the CaHA microspheres themselves) plus delayed collagen stimulation. Lasts 12–18 months. Denser than HA, so better for deep folds and hand rejuvenation; not suitable for lips or fine lines

Biostimulators demand patient education: results are not immediate, compliance with treatment schedules matters, and the mechanism is unfamiliar to many consumers. Practices using biostimulators typically charge a premium per treatment and see higher patient lifetime value.

Recent FDA approvals have introduced fillers engineered for specific mechanical properties and facial dynamics.

• RHA (Resilient Hyaluronic Acid): Revance's RHA Collection (RHA 2, RHA 3, RHA 4) uses a proprietary crosslinking method that preserves HA flexibility, allowing it to move naturally with facial expression. RHA 2 is lighter (lips, fine lines); RHA 3 is medium (nasolabial folds, marionette lines); RHA 4 is dense (deep folds, cheek/chin augmentation). Longevity is comparable to traditional HA (9–15 months depending on product), but the dynamic response may improve patient satisfaction and reduce the "overfilled" appearance. RHA commands a modest price premium over standard HA
• Skinvive by Juvéderm: Allergan Aesthetics' newest indication (FDA-approved for neck appearance improvement) is a microdroplet HA formulation designed for superficial placement and skin quality enhancement rather than volume replacement. Represents a shift toward preventive and maintenance treatments

These products appeal to practices targeting higher-end, aesthetically sophisticated patients willing to pay for perceived naturalness and longevity.

Filler choice should match anatomical need and patient expectation:

• Lips: Light-crosslink HA (Silk, Ultra XC) or RHA 2; avoid dense fillers that create stiffness or migration
• Nasolabial folds and marionette lines: Medium-crosslink HA or RHA 3; these are high-movement areas, so dynamic formulations reduce "frozen" appearance
• Cheeks and midface: Medium to heavy HA (Voluma, Volux, RHA 4) or PLLA for gradual lift; CaHA also effective
• Temples: Restylane Contour (FDA-approved for temple hollowing) or heavy HA; temples require structural support and minimal migration risk
• Jawline and chin: Heavy HA, RHA 4, or CaHA for definition and projection; these areas tolerate and benefit from denser products
• Under-eye and tear trough: Light HA only (Silk, Belotero); risk of Tyndall effect (blue discoloration) with darker formulations; superficial placement critical
• Hands: CaHA (Radiesse) preferred; HA can migrate and diffuse in thin skin

Mismatched placement (e.g., heavy HA in lips, light HA in cheeks) reduces longevity and patient satisfaction.

Filler pricing and rebate structure directly impact practice margin. The three major loyalty platforms are:

• Alle (Allergan Aesthetics/AbbVie): Tiered rebates based on annual toxin + filler volume; higher rebates at higher spend tiers. Alle also offers patient financing (CareCredit integration), which increases conversion. Allergan's market dominance (Juvéderm, Voluma, Volux, Skinvive) makes Alle attractive for high-volume practices
• Aspire (Galderma): Rebate structure tied to Restylane + Sculptra + Radiesse volume. Galderma's recent FDA approvals (Restylane Contour for temples, RHA Collection) expand the menu. Aspire also bundles device partnerships
• Evolus Rewards (Evolus): Nucelis (HA) and Jeuveau (neuromodulator) rebates; Evolus competes on aggressive pricing and rebate percentages, appealing to price-sensitive or independent practices

Per-syringe cost varies by product and volume tier: HA syringes typically range $150–$350 wholesale (depending on crosslink and manufacturer); PLLA vials $400–$600; CaHA $300–$400. Practices should model annual filler volume, compare rebate tiers across platforms, and factor in patient financing integration. Switching loyalty programs mid-year is costly (rebate cliffs), so commitment matters.

Longevity claims drive patient retention and lifetime value. Be precise:

• Light HA: 6–9 months; schedule retreat appointments at 6-month mark to maintain consistency
• Medium HA: 9–12 months; most practices see optimal results at 9 months, with gradual fade by 12
• Heavy HA: 12–18 months; some patients report 18+ months in low-movement areas (cheeks); others fade by 12. Set expectations conservatively
• PLLA: 24+ months; results peak at 3 months post-final injection; gradual fade thereafter. Patients often retreat at 18–24 months
• CaHA: 12–18 months; similar to heavy HA but may persist longer in dense areas
• RHA: 9–15 months depending on product; marketed as comparable to traditional HA but with improved dynamics

Longevity varies by patient metabolism, injection depth, and area. Practices should track retreat intervals in their EMR and use this data to set realistic expectations and optimize scheduling. Offering "maintenance" packages (e.g., 3 syringes annually at a discount) locks in revenue and improves patient compliance.